Trial Profile

A Phase II trial to evaluate the efficacy of Bortezomib, Cytarabine, and Dexamethasone in patients with relapsed or refractory mantle cell lymphoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Pegfilgrastim (Primary) ; Pegteograstim (Primary)
Indications Mantle-cell lymphoma
Focus Therapeutic Use
Acronyms BATMAN

Most Recent Events

15 Jun 2023 Results assessing the efficacy and safety of bortezomib, cytarabine, and dexamethasone (VAD) in patients with Relapsed or Refractory Mantle Cell Lymphoma presented at the 28th Congress of the European Haematology Association
16 Mar 2023 Status changed from recruiting to completed.
24 Sep 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com